TABLE 1.
The information on antiviral hepatitis B treatment nucleoside analogs medications.
| Category | Bid-winning/Non-winning products | Branded/Generic drugs | DDD (mg) | Number of products (n) | Number of pharmaceutical manufacturers (n) |
|---|---|---|---|---|---|
| Selected medications | |||||
| Entecavir | Bid-winning products | Generic | 0.5 | 1 | 1 |
| Entecavir | Non-winning products | Branded | 0.5 | 2 | 1 |
| Entecavir | Non-winning products | Generic | 0.5 | 31 | 10 |
| Tenofovir Fumarate | Bid-winning products | Generic | 300 | 2 | 1 |
| Tenofovir Fumarate | Non-winning products | Branded | 300 | 4 | 3 |
| Tenofovir Fumarate | Non-winning products | Generic | 300 | 8 | 5 |
| Alternative medications | |||||
| Lamivudine | - | - | 25 | 10 | 7 |
| Telbivudine | - | - | 600 | 1 | 1 |
| Adefovir dipivoxil | - | - | 10 | 30 | 17 |
DDD: Defined Daily Dose. The bold value meaning was classification of antiviral medications of hepatitis B virus in this study.